A Renaissance of Clinical Trials for IgA Nephropathy—Can the Same Occur for Membranous Nephropathy?
By:
Joyita Bharati Boston Medical Center, Boston, Massachusetts

Search for other papers by Joyita Bharati in
Current site
Google Scholar
PubMed Close
and
Laurence H. Beck Jr Boston Medical Center, Boston, Massachusetts

Chobanian & Avedisian School of Medicine, Boston University, Boston, Massachusetts

Search for other papers by Laurence H. Beck Jr in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 24: Issue 1
Published Online:
Mar 2025
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2025 by the American Society of Nephrology 2025
Page Count:
6
Article Category:
Research Article
Print Publication Date:
01 Mar 2025
Published Online:
Mar 2025
  • 1.

    Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, et al.: IgA nephropathy. Nat Rev Dis Primers 9: 67, 2023 PubMed

  • 2.

    Alsharhan L, Beck LH Jr.: Membranous nephropathy: Core curriculum 2021. Am J Kidney Dis 77: 440–453, 2021 PubMed

  • 3.

    Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, et al.: Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364: 616–626, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, Zanoni F, Liu L, Mladkova N, et al.: Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet 55: 1091–1105, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Xu X, Wang G, Chen N, Lu T, Nie S, Xu G, et al.: Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol 27: 3739–3746, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Cremoni M, Agbekodo S, Teisseyre M, Zorzi K, Brglez V, Benzaken S, et al.: Toxic occupational exposures and membranous nephropathy. Clin J Am Soc Nephrol 17: 1609–1619, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Thompson A, Carroll K, Inker LA, Floege J, Perkovic V, Boyer-Suavet S, et al.: Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 14: 469–481, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Inker LA, Heerspink HJL, Tighiouart H, Chaudhari J, Miao S, Diva U, et al.: Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: An individual participant meta-analysis. Am J Kidney Dis 78: 340–349.e1, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry: Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177–3183, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al.: Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 18: 727–738, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, et al.; DUPRO steering committee and PROTECT Investigators: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402: 2077–2090, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, et al.; NefIgArd trial investigators: Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402: 859–870, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, et al.: Alternative complement pathway inhibition with iptacopan in IgA nephropathy [published online ahead of print Oct 25, 2024]. N Engl J Med, doi:10.1056/NEJMoa2410316 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, et al.; ENVISION Trial Investigators Group: A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med 390: 20–31, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Thompson A, Cattran DC, Blank M, Nachman PH: Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 26: 2930–2937, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, et al.; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697–704, 2010 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Beck LH Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al.: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21, 2009 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Hoxha E, Reinhard L, Stahl RAK: Membranous nephropathy: New pathogenic mechanisms and their clinical implications. Nat Rev Nephrol 18: 466–478, 2022 PubMed

  • 19.

    Kistler AD, Salant DJ: Complement activation and effector pathways in membranous nephropathy. Kidney Int 105: 473–483, 2024 PubMed

  • 20.

    Haddad G, Lorenzen JM, Ma H, de Haan N, Seeger H, Zaghrini C, et al.: Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J Clin Invest 131: e140453, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Gao S, Cui Z, Zhao MH: Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy. J Am Soc Nephrol 33: 1742–1756, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Lerner GB, Virmani S, Henderson JM, Francis JM, Beck LH Jr.: A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy. Kidney Int 100: 289–300, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al.; TESTING Study Group: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 327: 1888–1898, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, et al.; GEMRITUX Study Group: Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up. J Am Soc Nephrol 28: 348–358, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al.; MENTOR Investigators: Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381: 36–46, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Fernandez-Juarez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontan F, et al.; STARMEN Investigators: The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int 99: 986–998, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al.: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444–450, 1998 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al.: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899–1904, 2007 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Bharati J, Waguespack DR, Beck LH Jr.: Membranous nephropathy: Updates on management. Adv Kidney Dis Health 31: 299–308, 2024 PubMed

  • 30.

    Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, et al.; RI-CYCLO Investigators: Rituximab or cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO randomized trial. J Am Soc Nephrol 32: 972–982, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC: A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol 28: 421–430, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) Workgroup: 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100: S1–S276, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Tomas NM, Schnarre A, Dehde S, Lucas R, Hermans-Borgmeyer I, Kretz O, et al.: Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy. Kidney Int 104: 916–928, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Hofstra JM, Beck LH Jr., Beck DM, Wetzels JF, Salant DJ: Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 1286–1291, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Beck LH Jr., Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al.: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543–1550, 2011 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Radice A, Trezzi B, Maggiore U, Pregnolato F, Stellato T, Napodano P, et al.: Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev 15: 146–154, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pelle T, Gaspari F, et al.: Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26: 2545–2558, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, et al.; MENTOR Trial Investigators: Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy. Clin J Am Soc Nephrol 18: 1283–1293, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Du Y, Li J, He F, Lv Y, Liu W, Wu P, et al.: The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis. PLoS One 9: e104936, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Vink CH, Logt AV, van der Molen RG, Hofstra JM, Wetzels JFM: Antibody-guided therapy in phospholipase A2 receptor-associated membranous nephropathy. Kidney Int Rep 8: 432–441, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Bobart SA, De Vriese AS, Pawar AS, Zand L, Sethi S, Giesen C, et al.: Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int 95: 429–438, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Tampoia M, Migliucci F, Villani C, Abbracciavento L, Rossini M, Fumarulo R, et al.: Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy. J Nephrol 31: 899–905, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Liu Y, Li X, Ma C, Wang P, Liu J, Su H, et al.: Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients. Clin Chim Acta 476: 9–14, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Prunotto M, Nachman PH, Gillespie B, Beck LH Jr., Thompson AM, et al.: Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: Results of a Nephcure Membranous Nephropathy Workshop. Kidney Int 2025, in press

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Su X, Wu B, Tie X, Guo X, Feng R, Qiao X, et al.: Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy. Kidney Int Rep 9: 2386–2398, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Hu X, Zhang M, Xu J, Gao C, Yu X, Li X, et al.: Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy. Clin J Am Soc Nephrol 19: 1594–1602, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, et al.: Phase 1b/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy. Kidney Int Rep 9: 2635–2647, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Tomas NM, Beck LH Jr., Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al.: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371: 2277–2287, 2014 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Zaghrini C, Seitz-Polski B, Justino J, Dolla G, Payre C, Jourde-Chiche N, et al.: Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int 95: 666–679, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Al-Rabadi LF, Caza T, Trivin-Avillach C, Rodan AR, Andeen N, Hayashi N, et al.: Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy. J Am Soc Nephrol 32: 1666–1681, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Reinhard L, Machalitza M, Wiech T, Grone HJ, Lasse M, Rinschen MM, et al.: Netrin G1 is a novel target antigen in primary membranous nephropathy. J Am Soc Nephrol 33: 1823–1831, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 1227 1227 1142
Full Text Views 145 145 57
PDF Downloads 216 216 77